Shandong Xinhua Pharmaceutical's (HKG:0719, SHE:000756) Tramadol Hydrochloride Sustained-release Tablets have passed China's National Medical Products Administration's quality and efficacy consistency evaluation, a Friday bourse filing said.
The drug is a centrally acting opioid analgesic, indicated for moderate to severe pain.